SCHEMBL3300407

SCHEMBL3300407

FC(F)(F)c1cc(NC(=S)NCCc2ccc(Cl)cc2Cl)cc(C(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
MAPT P10636 9/20 0.50
ALOX12 P18054 5/20 0.50
CNR1 P21554 1/20 0.50
MYC P01106 1/20 0.50
MAX P61244 1/20 0.50
PPARG P37231 1/20 0.50
NCOA3 Q9Y6Q9 1/20 0.50
MEN1 O00255 7/20 0.49
KMT2A Q03164 7/20 0.49
LMNA P02545 6/20 0.49
HTT P42858 4/20 0.49
CYP1A2 P05177 3/20 0.49
CYP3A4 P08684 3/20 0.49
CYP2D6 P10635 3/20 0.49
CYP2C19 P33261 3/20 0.49
XBP1 P17861 2/20 0.49
MAPK1 P28482 1/20 0.49
POLB P06746 1/20 0.49
CYP2C9 P11712 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3301650 0.88 MAPT (0.66) ALDH1A1MAPTALOX12MYCMAX
SCHEMBL3297435 0.84 MAPT (0.64) ALDH1A1MAPTALOX12CNR1MYC
SCHEMBL3305182 0.81 NPC1 (0.60) ALDH1A1MAPTALOX12CNR1MYC
SCHEMBL7574479 0.79 CNR1 (0.60) ALDH1A1MAPTALOX12CNR1PPARG
SCHEMBL8164838 0.76 LMNA (0.57) ALDH1A1MAPTCNR1MEN1KMT2A
SCHEMBL3300939 0.76 MAPT (0.79) ALDH1A1MAPTALOX12MYCMAX
SCHEMBL3300428 0.76 MYC (0.75) ALDH1A1MAPTMYCMAXMEN1
SCHEMBL18786284 0.75 MYC (0.61) ALDH1A1MAPTMYCMAXMEN1
SCHEMBL7574470 0.75 CNR1 (0.62) ALDH1A1MAPTALOX12CNR1PPARG
SCHEMBL17596506 0.74 CDK1 (0.71) ALDH1A1MAPTMYCMAXMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2010-04-15 US disclosed
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2010-04-15 US disclosed
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2010-04-15 US disclosed
EP-2074085-A2 ANTI-INFECTIVE THIOUREA COMPOUNDS Lica Pharmaceuticals A/S (DK) 2009-07-01 EP disclosed
WO-2008043840-A2 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2008-04-17 WO disclosed
WO-2008043840-A2 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS TST, TPX2, TPMT ALDH1A1 4109/4885MAPT 4691/4885ALOX12 2250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.